241 related articles for article (PubMed ID: 22688761)
1. Easy and efficient protocols for working with recombinant vaccinia virus MVA.
Kremer M; Volz A; Kreijtz JH; Fux R; Lehmann MH; Sutter G
Methods Mol Biol; 2012; 890():59-92. PubMed ID: 22688761
[TBL] [Abstract][Full Text] [Related]
2. Construction and isolation of recombinant MVA.
Staib C; Drexler I; Sutter G
Methods Mol Biol; 2004; 269():77-100. PubMed ID: 15114009
[TBL] [Abstract][Full Text] [Related]
3. Isolation of recombinant MVA using F13L selection.
Sánchez-Puig JM; Lorenzo MM; Blasco R
Methods Mol Biol; 2012; 890():93-111. PubMed ID: 22688762
[TBL] [Abstract][Full Text] [Related]
4. The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use.
Di Lullo G; Soprana E; Panigada M; Palini A; Agresti A; Comunian C; Milani A; Capua I; Erfle V; Siccardi AG
J Virol Methods; 2010 Feb; 163(2):195-204. PubMed ID: 19778556
[TBL] [Abstract][Full Text] [Related]
5. Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection.
Di Lullo G; Soprana E; Panigada M; Palini A; Erfle V; Staib C; Sutter G; Siccardi AG
J Virol Methods; 2009 Mar; 156(1-2):37-43. PubMed ID: 19038289
[TBL] [Abstract][Full Text] [Related]
6. [Design and construction of transfer vectors in order to obtain recombinant modified vaccinia virus Ankara (MVA)].
Ferrer MF; Zanetti FA; Calamante G
Rev Argent Microbiol; 2007; 39(3):138-42. PubMed ID: 17987847
[TBL] [Abstract][Full Text] [Related]
7. High level protein expression in mammalian cells using a safe viral vector: modified vaccinia virus Ankara.
Hebben M; Brants J; Birck C; Samama JP; Wasylyk B; Spehner D; Pradeau K; Domi A; Moss B; Schultz P; Drillien R
Protein Expr Purif; 2007 Dec; 56(2):269-78. PubMed ID: 17892951
[TBL] [Abstract][Full Text] [Related]
8. [Modified vaccinia virus ankara (MVA)--development as recombinant vaccine and prospects for use in veterinary medicine].
Volz A; Fux R; Langenmayer MC; Sutter G
Berl Munch Tierarztl Wochenschr; 2015; 128(11-12):464-72. PubMed ID: 26697713
[TBL] [Abstract][Full Text] [Related]
9. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line.
Carroll MW; Moss B
Virology; 1997 Nov; 238(2):198-211. PubMed ID: 9400593
[TBL] [Abstract][Full Text] [Related]
10. Marker rescue of the host range restriction defects of modified vaccinia virus Ankara.
Wyatt LS; Carroll MW; Czerny CP; Merchlinsky M; Sisler JR; Moss B
Virology; 1998 Nov; 251(2):334-42. PubMed ID: 9837798
[TBL] [Abstract][Full Text] [Related]
11. Nonreplicating vaccinia vector efficiently expresses recombinant genes.
Sutter G; Moss B
Proc Natl Acad Sci U S A; 1992 Nov; 89(22):10847-51. PubMed ID: 1438287
[TBL] [Abstract][Full Text] [Related]
12. Vectors for recombinational cloning and gene expression in mammalian cells using modified vaccinia virus Ankara.
Pradeau-Aubreton K; Ruff M; Garnier JM; Schultz P; Drillien R
Anal Biochem; 2010 Sep; 404(1):103-5. PubMed ID: 20450873
[TBL] [Abstract][Full Text] [Related]
13. Early gene expression of vaccinia virus strains replicating (Praha) and non-replicating (modified vaccinia virus strain Ankara, MVA) in mammalian cells.
Nemecková S; Hainz P; Otáhal P; Gabriel P; Sroller V; Kutinová L
Acta Virol; 2001; 45(4):243-7. PubMed ID: 11885931
[TBL] [Abstract][Full Text] [Related]
14. Construction and evaluation of a new triple-gene expression cassette vaccinia virus shuttle vector.
Du S; Li C; Wang Y; Liu C; Ren D; Li Y; Qin Y; Wang M; Sun D; Zhu N; Jin N
J Virol Methods; 2012 Nov; 185(2):175-83. PubMed ID: 22766182
[TBL] [Abstract][Full Text] [Related]
15. Generation of recombinant vaccinia viruses.
Earl PL; Moss B; Wyatt LS; Carroll MW
Curr Protoc Mol Biol; 2001 May; Chapter 16():Unit16.17. PubMed ID: 18265124
[TBL] [Abstract][Full Text] [Related]
16. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.
Sutter G; Staib C
Curr Drug Targets Infect Disord; 2003 Sep; 3(3):263-71. PubMed ID: 14529359
[TBL] [Abstract][Full Text] [Related]
17. Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination.
Breathnach CC; Rudersdorf R; Lunn DP
Vet Immunol Immunopathol; 2004 Apr; 98(3-4):127-36. PubMed ID: 15010222
[TBL] [Abstract][Full Text] [Related]
18. Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.
Hornemann S; Harlin O; Staib C; Kisling S; Erfle V; Kaspers B; Häcker G; Sutter G
J Virol; 2003 Aug; 77(15):8394-407. PubMed ID: 12857909
[TBL] [Abstract][Full Text] [Related]
19. Functional F11L and K1L genes in modified vaccinia virus Ankara restore virus-induced cell motility but not growth in human and murine cells.
Zwilling J; Sliva K; Schwantes A; Schnierle B; Sutter G
Virology; 2010 Sep; 404(2):231-9. PubMed ID: 20627347
[TBL] [Abstract][Full Text] [Related]
20. Non-replicating vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase.
Sutter G; Ohlmann M; Erfle V
FEBS Lett; 1995 Aug; 371(1):9-12. PubMed ID: 7664891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
